Lucentis Shown Effective in Treating Diabetic Macular Edema in Second Trial

March 28, 2011

Genentech, a member of the Roche Group, announced Friday, that the second of two Phase III trials (known as RIDE) evaluating Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME) met its primary endpoint, which was showing that after 24 months a significantly greater number of patients who received Lucentis, compared to those who received placebo (sham) injections, were able to read at least 15 additional letters on an eye chart than they could at the start of the study. The safety results were consistent with previous Lucentis Phase III trials and no new significant safety findings were observed.

Click here to read the full release.

The results of the RIDE trial are consistent with data from RISE trial released earlier in March showing patients with diabetic macular edema who received Lucentis experienced substantial improvement in vision.




Jump down to form below to submit your own comments

Comments are closed.